{"prompt": "['Novartis', 'Confidential', 'Page 4', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '7.3', 'Liver safety monitoring', '60', '7.4', 'Renal safety monitoring', '61', '7.5', 'Reporting of study treatment errors including misuse/abuse', '62', '7.6', 'Pregnancy reporting', '62', '7.7', 'Idiosyncratic drug reactions monitoring', '63', '8', 'Data review and database management', '63', '8.1', 'Site monitoring', '63', '8.2', 'Data collection', '64', '8.3', 'Database management and quality control', '64', '8.4', 'Data Monitoring Committee', '65', '8.5', 'Adjudication Committee', '65', '9', 'Data analysis', '65', '9.1', 'Analysis sets', '65', '9.2', 'Patient demographics and other baseline characteristics', '66', '9.3', 'Treatments', '66', '9.4', 'Analysis of the primary variable(s)', '66', '9.4.1', 'Primary Variable(s)', '67', '9.4.2', 'Statistical model, hypothesis, and method of analysis', '67', '9.4.3', 'Handling of missing values/censoring/discontinuations', '69', '9.4.4', 'Supportive analyses', '69', '9.5', 'Analysis of secondary variables', '70', '9.5.1', 'Efficacy variables', '70', '9.5.2', 'Safety variables', '72', '73', '73', '9.7', 'Interim analyses', '73', '9.8', 'Sample size calculation', '73', '9.8.1', 'Power for the secondary objectives', '74', '10 Ethical considerations', '75', '10.1', 'Regulatory and ethical compliance', '75', '10.2', 'Informed consent procedures', '75', '10.3', 'Responsibilities of the investigator and IRB/IEC', '76', '10.4', 'Publication of study protocol and results', '76', '10.5', 'Quality Control and Quality Assurance', '76', '11 Protocol adherence', '76', '11.1', 'Protocol amendments', '77']['Novartis', 'Confidential', 'Page 5', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '12 References', '77', '13 Appendix 1: Clinically notable laboratory values and vital signs', '80', '14', 'Appendix 2: Liver event and laboratory trigger definitions and follow-up', 'requirements', '81', '15 Appendix 3: Specific Renal Alert Criteria and Actions', '83', '16 Appendix 4: List of idiosyncratic drug reactions (IDRs) for investigators', '84', '17 Appendix 5: Spirometry Guidance', '85', '17.1 References for appendix', '87', '18 Appendix 6: Estimated equivalence of inhaled corticosteroids', '88', '19 Appendix 7: Asthma Control Questionnaire (ACQ-5)', '89', '20 Appendix 8 : Asthma Quality of Life Questionnaire for 12 years and older', '(AQLQ+12)', '91', '97', 'List of tables', 'Table 2-1', 'Objectives and related endpoints', '16', 'Table 5-1', 'Medications allowed under certain conditions', '32', 'Table 5-2', 'Medications to be withheld prior to spirometry', '34', 'Table 5-3', 'Prohibited medication', '34', 'Table 6-1', 'Assessment schedule', '41', 'Table 7-1', 'Guidance for capturing the study treatment errors including', 'misuse/abuse', '62', 'Table 9-1', 'Result of power simulations for the primary variable', '74', 'Table 9-2', 'Power simulations for secondary variables', '75', 'Table 14-1', 'Liver Event and Laboratory Trigger Definitions', '81', 'Table 14-2', 'Follow Up Requirements for Liver Events and Laboratory Triggers 81', 'Table 15-1', 'Specific Renal Alert Criteria and Actions', '83', 'Table 16-1', 'Definition of potential idiosyncratic drug reactions', '84', 'List of figures', 'Figure 3-1', 'Study design', '18', 'Figure 9-1', 'Closed testing procedure for primary and secondary objectives', '68']\n\n###\n\n", "completion": "END"}